Wendy Stock to Tumor Suppressor Protein p53
This is a "connection" page, showing publications Wendy Stock has written about Tumor Suppressor Protein p53.
Connection Strength
0.433
-
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.
Score: 0.179
-
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
Score: 0.115
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.
Score: 0.045
-
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334.
Score: 0.039
-
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
Score: 0.033
-
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52.
Score: 0.022